Clinical Trial Update: Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of a gene therapy using anti-HER-2–expressing cells to treat metastatic cancer was terminated. Results were posted in February 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Anti-HER-2 cell therapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-02-14